Retatrutide is an investigational triple-receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, distinguishing it from semaglutide and tirzepatide
[DOI] [PMC free article] [PubMed] [Google Scholar] 60.Castilla-Cortazar I, Aguirre GA, Femat-Roldan G, Martin-Estal I, Espinosa L
Most cases appear consistent with telogen effluvium, a reversible form of diffuse shedding triggered by physiological stress
Diet and lifestyle factors that affect your dose response Two people can take exactly the same 50-unit draw from the same concentration vial and have very different experiences
For type 2 diabetes mellitus, tirzepatide (Mounjaro) received FDA approval in May 2022 as an adjunct to diet and exercise to improve glycemic control in adults
For guidance on managing transitions between tirzepatide and semaglutide during tapering, that comparison covers equivalent doses across both peptides